Beyond Belviq: Reinventing Arena To Focus On Phase II Candidates

Dr. Amit Munshi, new CEO of Arena Pharmaceuticals, has already made several changes in the company’s focus and direction as it reduces its commitment to Belviq. He talked to Mike Ward about progress to date.

Video interview
Arena's CEO Amit Munshi talks to Scrip at Biotech Showcase

In the six months after joining Arena Pharmaceuticals Inc. as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq (lorcaserin), which it has partnered with Eisai Co. Ltd.; spinning out the discovery research activities into a new company, Beacon Discovery; and prioritizing three Phase II programs with readouts in 2017.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By 

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By 

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By 

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.